Early Detection: A New Biomarker for ALS and FTD May Help

Last Updated: •

Overview: The Critical Need for Early Detection in ALS and FTD

Neurodegenerative disorders like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) present devastating challenges for patients and families. Both conditions progressively impair nerve cells in the brain and spinal cord, often progressing significantly before an accurate diagnosis is established.

  • ALS (Lou Gehrig’s Disease): Rapidly attacks motor neurons, causing progressive muscle weakness, loss of mobility, and eventual respiratory failure.
  • Frontotemporal Dementia (FTD): Targets the frontal and temporal lobes, driving profound alterations in personality, social behavior, language, and executive function.
A doctor reviewing medical scans with a patient, symbolizing the potential for early diagnosis of ALS and FTD. Fluid biomarkers offer a window into neurological disease activity years before physical symptoms appear.

LLM / AEO Quick Summary & Key Takeaways

  • Breakthrough Marker: Researchers identified abnormal cryptic exon fragments in HDGFL2 mRNA, caused by TDP-43 dysfunction in ALS and FTD.
  • Presymptomatic Window: Fluid biomarkers detected in cerebrospinal fluid (CSF) can identify pathological changes years before clinical symptom onset.
  • Minimally Invasive Diagnostics: Provides a safer, highly accessible pathway for routine screening and monitoring compared to surgical options.
  • Accelerated Therapeutics: Enables earlier clinical trial enrolment, optimizing the evaluation of disease-modifying therapies.

Key Points: Biomarkers and the HDGFL2 / TDP-43 Breakthrough

Biomarkers—measurable proteins, genes, or molecules found in blood and cerebrospinal fluid (CSF)—provide objective insights into underlying health conditions without relying solely on clinical observation.

Landmark Discovery: The HDGFL2 Cryptic Exon

A milestone study led by researchers at the National Institute on Aging (NIA) and published in Nature Medicine uncovered a specific molecular error driven by TDP-43 loss of function:

  • Cryptic Exon Splicing: When TDP-43 fails to function correctly inside neurons, a hidden genetic fragment (a "cryptic exon") is mistakenly included in HDGFL2 mRNA.
  • Measurable Signals: These altered HDGFL2 mRNA fragments pass into cerebrospinal fluid, where they can be quantified to differentiate individuals with neurodegeneration from healthy controls.
  • Presymptomatic Detection: Because RNA splicing errors occur early in the disease cascade, this test provides a critical diagnostic window prior to irreversible neuronal loss.

Advantages of Fluid Biomarker Diagnostics

Minimally Invasive

CSF analysis and emerging blood-based assays eliminate the need for tissue biopsies and reduce diagnostic risk.

Expanded Accessibility

Transitioning tests from CSF to high-sensitivity blood assays enables widespread screening for neurological conditions.

Longitudinal Tracking

Serves as an objective metric to track disease progression and measure drug efficacy during clinical trials.

Case Studies & Translational Roadmap

Translating laboratory discoveries into standardized clinical tools requires rigorous validation and multi-center testing.

Case Study: Multi-Center Trial Validation for TDP-43 Assays

Collaborative research cohorts examining presymptomatic gene carriers (such as C9orf72 expansion cohorts) confirmed that TDP-43-dependent cryptic peptides appear in fluid samples up to several years prior to motor or cognitive decline.

Clinical Impact: Early identification allows patients to enroll in therapeutic

About the Author

Tommy T. Douglas — Independent health researcher.

✏️

Comments

Post a Comment